Network-Level Mechanisms for Preclinical Alzheimer's Disease Development

• Status: Active, not recruiting
• Trial end date: 2021-05-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this project is to test the hypothesis that AGB101 low dose levetiracetam extended release formulation can reduce abnormal hyperfunctional activity in the hippocampus in normal, healthy adults who are APOE 4 carriers. The investigators will compare the results to normal, healthy adults who are APOE 4 non-carriers.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Medical College of Wisconsin
• Collaborator: National Institute on Aging (NIA)
• Treatments: Etiracetam; Piracetam

Criteria

Inclusion Criteria:

• Fluent in English

• At least eight (8) years of education

• Geriatric Depression Scale (GDS) (62) score < 6

• Hachinski Ischemic Score ≤ 4

• Normal general cognitive function as well as 1) normal memory function, documented by MOCA score of 23 or greater, and a RBANS Delayed Memory Index score of 85 or greater.

Exclusion Criteria:

• Neurological disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or a history of significant head trauma or known structural brain abnormalities

• Major psychiatric disease or chronic unstable medical conditions

• History of drug abuse

• History of alcohol abuse (4 or greater drinks per day on average)

• Unable to complete MRI scans (no Pacemaker/Defibrillator)

• Known clinically significant abnormalities in B12 or thyroid function tests

• End Stage Renal Disease (ESRD)

• Hemodialysis (HD)